<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37376204</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>17</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Research Progress of Aluminum Phosphate Adjuvants and Their Action Mechanisms.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1756</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics15061756</ELocationID><Abstract><AbstractText>Although hundreds of different adjuvants have been tried, aluminum-containing adjuvants are by far the most widely used currently. It is worth mentioning that although aluminum-containing adjuvants have been commonly applied in vaccine production, their acting mechanism remains not completely clear. Thus far, researchers have proposed the following mechanisms: (1) depot effect, (2) phagocytosis, (3) activation of pro-inflammatory signaling pathway NLRP3, (4) host cell DNA release, and other mechanisms of action. Having an overview on recent studies to increase our comprehension on the mechanisms by which aluminum-containing adjuvants adsorb antigens and the effects of adsorption on antigen stability and immune response has become a mainstream research trend. Aluminum-containing adjuvants can enhance immune response through a variety of molecular pathways, but there are still significant challenges in designing effective immune-stimulating vaccine delivery systems with aluminum-containing adjuvants. At present, studies on the acting mechanism of aluminum-containing adjuvants mainly focus on aluminum hydroxide adjuvants. This review will take aluminum phosphate as a representative to discuss the immune stimulation mechanism of aluminum phosphate adjuvants and the differences between aluminum phosphate adjuvants and aluminum hydroxide adjuvants, as well as the research progress on the improvement of aluminum phosphate adjuvants (including the improvement of the adjuvant formula, nano-aluminum phosphate adjuvants and a first-grade composite adjuvant containing aluminum phosphate). Based on such related knowledge, determining optimal formulation to develop effective and safe aluminium-containing adjuvants for different vaccines will become more substantiated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sinovac Biotech Sciences Co., Ltd., Beijing 102601, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus &amp; Enterovirus Vaccines, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102619, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Dejia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sinovac Life Sciences Co., Ltd., Beijing 102601, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kaixi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sinovac Life Sciences Co., Ltd., Beijing 102601, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Zhongyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus &amp; Enterovirus Vaccines, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102619, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Yening</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sinovac Life Sciences Co., Ltd., Beijing 102601, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aluminum phosphate adjuvants</Keyword><Keyword MajorTopicYN="N">aluminum phosphate improvement</Keyword><Keyword MajorTopicYN="N">immune stimulation mechanism</Keyword><Keyword MajorTopicYN="N">preclinical and clinical</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The company had played role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>1</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37376204</ArticleId><ArticleId IdType="pmc">PMC10305650</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics15061756</ArticleId><ArticleId IdType="pii">pharmaceutics15061756</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shirodkar S., Hutchinson R.L., Perry D.L., White J.L., Hem S.L. Aluminum compounds used as adjuvants in vaccines. Pharm. Res. 1990;7:1282–1288. doi: 10.1023/A:1015994006859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1015994006859</ArticleId><ArticleId IdType="pubmed">2095567</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenny A.T. The antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol. 1926;29:38–40.</Citation></Reference><Reference><Citation>Temperton N.J., Quenelle D.C., Lawson K.M., Zuckerman J.N., Kern E.R., Griffiths P.D., Emery V.C. Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides. J. Med. Virol. 2003;70:86–90. doi: 10.1002/jmv.10357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.10357</ArticleId><ArticleId IdType="pubmed">12629648</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer S., HogenEsch H., Hem S.L. Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. Vaccine. 2003;21:1219–1223. doi: 10.1016/S0264-410X(02)00556-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(02)00556-X</ArticleId><ArticleId IdType="pubmed">12559801</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M., Wang W. Factors affecting alum–protein interactions. Int. J. Pharm. 2014;466:139–146. doi: 10.1016/j.ijpharm.2014.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2014.03.015</ArticleId><ArticleId IdType="pubmed">24607202</ArticleId></ArticleIdList></Reference><Reference><Citation>HogenEsch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front. Immunol. 2013;3:406. doi: 10.3389/fimmu.2012.00406.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00406</ArticleId><ArticleId IdType="pmc">PMC3541479</ArticleId><ArticleId IdType="pubmed">23335921</ArticleId></ArticleIdList></Reference><Reference><Citation>Soehnlein O., Zernecke A., Eriksson E.E., Rothfuchs A.G. Neutrophil secretion products pave the way for inflammatory monocytes. Blood. 2008;112:1461–1471. doi: 10.1182/blood-2008-02-139634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-02-139634</ArticleId><ArticleId IdType="pmc">PMC3400540</ArticleId><ArticleId IdType="pubmed">18490516</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones L.S., Peek L.J., Power J., Markham A., Yazzie B., Middaugh C.R. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J. Biol. Chem. 2005;280:13406–13414. doi: 10.1074/jbc.M500687200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M500687200</ArticleId><ArticleId IdType="pubmed">15684430</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen B., Sokolovska A., HogenEsch H., Hem S.L. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine. 2007;25:6618–6624. doi: 10.1016/j.vaccine.2007.06.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.06.049</ArticleId><ArticleId IdType="pubmed">17681647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghimire T.R., Benson R.A., Garside P., Brewer J.M. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunol. Lett. 2012;147:55–62. doi: 10.1016/j.imlet.2012.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2012.06.002</ArticleId><ArticleId IdType="pmc">PMC3477319</ArticleId><ArticleId IdType="pubmed">22732235</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan J., Jin S., Gilmartin L., Toth I., Hussein W.M., Stephenson R.J. Advances in Infectious Disease Vaccine Adjuvants. Vaccines. 2022;10:1120. doi: 10.3390/vaccines10071120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10071120</ArticleId><ArticleId IdType="pmc">PMC9316175</ArticleId><ArticleId IdType="pubmed">35891284</ArticleId></ArticleIdList></Reference><Reference><Citation>Bella A., Gesualdo F., Orsi A., Arcuri C., Chironna M., Loconsole D., Napoli C., Orsi G.B., Manini I., Montomoli E. Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A (H1N1) pdm09 viruses in the elderly in Italy, 2017–2018 season. Expert Rev. Vaccines. 2019;18:671–679.</Citation><ArticleIdList><ArticleId IdType="pubmed">31159616</ArticleId></ArticleIdList></Reference><Reference><Citation>Pifferi C., Fuentes R., Fernández-Tejada A. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. Nat. Rev. Chem. 2021;5:197–216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7829660</ArticleId><ArticleId IdType="pubmed">33521324</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurens M.B. RTS, S/AS01 vaccine (Mosquirix™): An overview. Hum. Vaccines Immunother. 2020;16:480–489. doi: 10.1080/21645515.2019.1669415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1669415</ArticleId><ArticleId IdType="pmc">PMC7227679</ArticleId><ArticleId IdType="pubmed">31545128</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharucha T., Ming D., Breuer J. A critical appraisal of ‘Shingrix’, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum. Vaccines Immunother. 2017;13:1789–1797. doi: 10.1080/21645515.2017.1317410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2017.1317410</ArticleId><ArticleId IdType="pmc">PMC5557227</ArticleId><ArticleId IdType="pubmed">28426274</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin R.S., Briones R. Quality control of commercial quillaja (Quillaja saponaria Molina) extracts by reverse phase HPLC. J. Sci. Food Agric. 2000;80:2063–2068. doi: 10.1002/1097-0010(200011)80:14&lt;2063::AID-JSFA750&gt;3.0.CO;2-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0010(200011)80:14&lt;2063::AID-JSFA750&gt;3.0.CO;2-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragupathi G., Gardner J.R., Livingston P.O., Gin D.Y. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev. Vaccines. 2014;10:463–470. doi: 10.1586/erv.11.18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.11.18</ArticleId><ArticleId IdType="pmc">PMC3658151</ArticleId><ArticleId IdType="pubmed">21506644</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G.H., Lim S.G. CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B) Update. Expert Rev. Vaccines. 2021;20:487–495. doi: 10.1080/14760584.2021.1908133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1908133</ArticleId><ArticleId IdType="pubmed">33783302</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieg A.M., Hartmann G., Yi A.K. Mechanism of action of CpG DNA. Curr. Top. Microbiol. Immunol. 2000;247:1–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10689776</ArticleId></ArticleIdList></Reference><Reference><Citation>Flarend R.E., Hem S.L., White J.L., Elmore D., Suckow M.A., Rudy A.C., Dandashli E.A. In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine. 1997;15:1314–1318. doi: 10.1016/S0264-410X(97)00041-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(97)00041-8</ArticleId><ArticleId IdType="pubmed">9302736</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeber S.J., White J.L., Hem S.L. Solubilization of aluminum-containing adjuvants by constituents of interstitial fluid. PDA J. Pharm. Sci. Technol. 1991;45:156–159.</Citation><ArticleIdList><ArticleId IdType="pubmed">1886045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooijman S., Vrieling H., Verhagen L., de Ridder J., de Haan A., van Riet E., Heck A.J., Kersten G.F., Pennings J.L., Metz B. Aluminum hydroxide and aluminum phosphate adjuvants elicit a different innate immune response. J. Pharm. Sci. 2022;111:982–990. doi: 10.1016/j.xphs.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2022.01.014</ArticleId><ArticleId IdType="pubmed">35090866</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 1998;32:155–172. doi: 10.1016/S0169-409X(98)00008-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-409X(98)00008-8</ArticleId><ArticleId IdType="pubmed">10837642</ArticleId></ArticleIdList></Reference><Reference><Citation>Hem S.L., White J.L. Structure and properties of aluminum-containing adjuvants. Pharm. Biotechnol. 1995;6:249.</Citation><ArticleIdList><ArticleId IdType="pubmed">7551220</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell L.S., Johnston C.T., Schulze D., Klein J., White J.L., Hem S.L. Aluminium phosphate adjuvants prepared by precipitation at constant pH. Part II: Physicochemical properties. Vaccine. 2000;19:282–287. doi: 10.1016/S0264-410X(00)00162-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(00)00162-6</ArticleId><ArticleId IdType="pubmed">10930683</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Ushio M., Burrell L.S., Wenslow B., Hem S.L. Analysis of aluminum hydroxyphosphate vaccine adjuvants by (27)Al MAS NMR. J. Pharm. Sci. 2000;89:311–321. doi: 10.1002/(SICI)1520-6017(200003)89:3&lt;311::AID-JPS3&gt;3.0.CO;2-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1520-6017(200003)89:3&lt;311::AID-JPS3&gt;3.0.CO;2-8</ArticleId><ArticleId IdType="pubmed">10707012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hem S.L., Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev. Vaccines. 2007;6:685. doi: 10.1586/14760584.6.5.685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.6.5.685</ArticleId><ArticleId IdType="pubmed">17931150</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeber S.J., White J.L., Hem S.L. Predicting the adsorption of proteins by aluminium-containing adjuvants. Vaccine. 1991;9:201–203. doi: 10.1016/0264-410X(91)90154-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410X(91)90154-X</ArticleId><ArticleId IdType="pubmed">2042392</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., HogenEsch H., Hem S.L. Change in the degree of adsorption of proteins by aluminum-containing adjuvants following exposure to interstitial fluid: Freshly prepared and aged model vaccines. Vaccine. 2001;20:80–85. doi: 10.1016/S0264-410X(01)00313-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00313-9</ArticleId><ArticleId IdType="pubmed">11567749</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinkovics J.G., Shirato E., Shullenberger C.C. Pertussis vaccine as immunological adjuvant in leukaemia and lymphoma. Br. Med. J. 1970;1:565. doi: 10.1136/bmj.1.5695.565-a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.1.5695.565-a</ArticleId><ArticleId IdType="pmc">PMC1699550</ArticleId><ArticleId IdType="pubmed">5265191</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosado-Vallado M., Mut-Martin M., del Rosario García-Miss M., Dumonteil E. Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana. Vaccine. 2005;23:5372–5379. doi: 10.1016/j.vaccine.2005.05.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.05.037</ArticleId><ArticleId IdType="pubmed">16054271</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulmer J., DeWitt C., Chastain M., Friedman A., Donnelly J., McClements W.a., Caulfield M., Bohannon K., Volkin D., Evans R. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine. 1999;18:18–28. doi: 10.1016/S0264-410X(99)00151-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(99)00151-6</ArticleId><ArticleId IdType="pubmed">10501231</ArticleId></ArticleIdList></Reference><Reference><Citation>Su W., Xu L., Fisher K., Smith J.G., Caulfield M.J. Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate. Vaccine. 2000;18:1227–1235.</Citation><ArticleIdList><ArticleId IdType="pubmed">10649624</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y.-Z., Wang W.-B., Li N., Wang S., Yu W.-Y., Sun Z.-W. Enhanced potency of individual and bivalent DNA replicon vaccines or conventional DNA vaccines by formulation with aluminum phosphate. Biologicals. 2010;38:658–663. doi: 10.1016/j.biologicals.2010.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2010.08.001</ArticleId><ArticleId IdType="pubmed">20805035</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S., Wang S., Grimes-Serrano J.M. Current progress of DNA vaccine studies in humans. Expert Rev. Vaccines. 2008;7:175–191. doi: 10.1586/14760584.7.2.175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.7.2.175</ArticleId><ArticleId IdType="pubmed">18324888</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwissa M., Lindblad E.B., Schirmbeck R., Reimann J. Codelivery of a DNA vaccine and a protein vaccine with aluminum phosphate stimulates a potent and multivalent immune response. J. Mol. Med. 2003;81:502–510. doi: 10.1007/s00109-003-0452-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-003-0452-9</ArticleId><ArticleId IdType="pubmed">12879151</ArticleId></ArticleIdList></Reference><Reference><Citation>He P., Zou Y., Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum. Vaccines Immunother. 2015;11:477–488. doi: 10.1080/21645515.2014.1004026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2014.1004026</ArticleId><ArticleId IdType="pmc">PMC4514166</ArticleId><ArticleId IdType="pubmed">25692535</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison W.T. Some Observations on the Use of Alum Precipitated Diphtheria Toxoid. Am. J. Public Health Nation’s Health. 1935;25:298–300. doi: 10.2105/AJPH.25.3.298.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.25.3.298</ArticleId><ArticleId IdType="pmc">PMC1559051</ArticleId><ArticleId IdType="pubmed">18014174</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J.C., Coulter A.R. Adjuvants—A classification and review of their modes of action. Vaccine. 1997;15:248–256. doi: 10.1016/S0264-410X(96)00183-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(96)00183-1</ArticleId><ArticleId IdType="pubmed">9139482</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., HogenEsch H., Regnier F.E., Hem S.L. Detoxification of endotoxin by aluminum hydroxide adjuvant. Vaccine. 2001;19:1747–1752. doi: 10.1016/S0264-410X(00)00394-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(00)00394-7</ArticleId><ArticleId IdType="pubmed">11166900</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheis W., Zott A., Schwanig M. The role of the adsorption process for production and control combined adsorbed vaccines. Vaccine. 2001;20:67–73. doi: 10.1016/S0264-410X(01)00317-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00317-6</ArticleId><ArticleId IdType="pubmed">11567747</ArticleId></ArticleIdList></Reference><Reference><Citation>Holt L.B. Developments in diphtheria prophylaxis. JAMA. 1950;144:1415.</Citation></Reference><Reference><Citation>Hutchison S., Benson R.A., Gibson V.B., Pollock A.H., Garside P., Brewer J.M. Antigen depot is not required for alum adjuvanticity. FASEB J. 2012;26:1272. doi: 10.1096/fj.11-184556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.11-184556</ArticleId><ArticleId IdType="pmc">PMC3289510</ArticleId><ArticleId IdType="pubmed">22106367</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R.K., Chang A.-C., Griffin P., Rivera R., Siber G.R. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine. 1996;14:1412–1416. doi: 10.1016/S0264-410X(96)00073-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(96)00073-4</ArticleId><ArticleId IdType="pubmed">8994315</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Wang X., Ito A. Tailoring inorganic nanoadjuvants towards next-generation vaccines. Chem. Soc. Rev. 2018;47:4954–4980. doi: 10.1039/C8CS00028J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C8CS00028J</ArticleId><ArticleId IdType="pubmed">29911725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghimire T.R. The mechanisms of action of vaccines containing aluminum adjuvants: An in vitro vs in vivo paradigm. Springerplus. 2015;4:181. doi: 10.1186/s40064-015-0972-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40064-015-0972-0</ArticleId><ArticleId IdType="pmc">PMC4406982</ArticleId><ArticleId IdType="pubmed">25932368</ArticleId></ArticleIdList></Reference><Reference><Citation>Danielsson R., Eriksson H. Aluminium adjuvants in vaccines–A way to modulate the immune response. Semin. Cell Dev. Biol. 2021;115:3–9. doi: 10.1016/j.semcdb.2020.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2020.12.008</ArticleId><ArticleId IdType="pubmed">33423930</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannhalter J., Neychev H., Zlabinger G., Ahmad R., Eibl M.M. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: Effect on antigen uptake and antigen presentation. Clin. Exp. Immunol. 1985;61:143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1577243</ArticleId><ArticleId IdType="pubmed">3876178</ArticleId></ArticleIdList></Reference><Reference><Citation>HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine. 2002;20:S34–S39. doi: 10.1016/S0264-410X(02)00169-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(02)00169-X</ArticleId><ArticleId IdType="pubmed">12184362</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolovska A., Hem S.L., Hogenesch H. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine. 2007;25:4575–4585. doi: 10.1016/j.vaccine.2007.03.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.03.045</ArticleId><ArticleId IdType="pubmed">17485153</ArticleId></ArticleIdList></Reference><Reference><Citation>Terhune T.D., Deth R.C. A role for impaired regulatory T cell function in adverse responses to aluminum adjuvant-containing vaccines in genetically susceptible individuals. Vaccine. 2014;32:5149–5155. doi: 10.1016/j.vaccine.2014.07.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.07.052</ArticleId><ArticleId IdType="pubmed">25066736</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinon F., Mayor A., Tschopp J. The inflammasomes: Guardians of the body. Annu. Rev. Immunol. 2009;27:229–265. doi: 10.1146/annurev.immunol.021908.132715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.021908.132715</ArticleId><ArticleId IdType="pubmed">19302040</ArticleId></ArticleIdList></Reference><Reference><Citation>Rock K.L., Latz E., Ontiveros F., Kono H. The sterile inflammatory response. Annu. Rev. Immunol. 2010;28:321–342. doi: 10.1146/annurev-immunol-030409-101311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-030409-101311</ArticleId><ArticleId IdType="pmc">PMC4315152</ArticleId><ArticleId IdType="pubmed">20307211</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenbarth S.C., Colegio O.R., O’Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453:1122–1126. doi: 10.1038/nature06939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06939</ArticleId><ArticleId IdType="pmc">PMC4804622</ArticleId><ArticleId IdType="pubmed">18496530</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., Fitzgerald K.A., Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 2008;9:847–856. doi: 10.1038/ni.1631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1631</ArticleId><ArticleId IdType="pmc">PMC2834784</ArticleId><ArticleId IdType="pubmed">18604214</ArticleId></ArticleIdList></Reference><Reference><Citation>Marichal T., Ohata K., Bedoret D., Mesnil C., Sabatel C., Kobiyama K., Lekeux P., Coban C., Akira S., Ishii K.J. DNA released from dying host cells mediates aluminum adjuvant activity. Nat. Med. 2011;17:996–1002. doi: 10.1038/nm.2403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2403</ArticleId><ArticleId IdType="pubmed">21765404</ArticleId></ArticleIdList></Reference><Reference><Citation>Mold M., Shardlow E., Exley C. Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations. Sci. Rep. 2016;6:31578. doi: 10.1038/srep31578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep31578</ArticleId><ArticleId IdType="pmc">PMC4981857</ArticleId><ArticleId IdType="pubmed">27515230</ArticleId></ArticleIdList></Reference><Reference><Citation>Shardlow E., Mold M., Exley C. The interaction of aluminium-based adjuvants with THP-1 macrophages in vitro: Implications for cellular survival and systemic translocation. J. Inorg. Biochem. 2020;203:110915. doi: 10.1016/j.jinorgbio.2019.110915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinorgbio.2019.110915</ArticleId><ArticleId IdType="pubmed">31751817</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.-G., Czabotar P.E., Policheni A.N., Caminschi I., San Wan S., Kitsoulis S., Tullett K.M., Robin A.Y., Brammananth R., van Delft M.F., et al. The Dendritic Cell Receptor Clec9A Binds Damaged Cells via Exposed Actin Filaments. Immunity. 2012;36:646–657. doi: 10.1016/j.immuni.2012.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.03.009</ArticleId><ArticleId IdType="pubmed">22483802</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruwona T.B., Xu H., Li X., Taylor A., Shi Y.C., Cui Z. Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles. Vaccine. 2016;34:3059–3067. doi: 10.1016/j.vaccine.2016.04.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.04.081</ArticleId><ArticleId IdType="pmc">PMC4920416</ArticleId><ArticleId IdType="pubmed">27155490</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl N.R., Silva M.T.d.O., Barbosa T.N., de Pinho R.B., Alves M.S.D., Portela R.W., Azevedo V.A.d.C., Borsuk S. Evaluation of the Association of Recombinant Proteins NanH and PknG from Corynebacterium pseudotuberculosis Using Different Adjuvants as a Recombinant Vaccine in Mice. Vaccines. 2023;11:519. doi: 10.3390/vaccines11030519.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030519</ArticleId><ArticleId IdType="pmc">PMC10051533</ArticleId><ArticleId IdType="pubmed">36992103</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezende A., Brum A., Bezerra F., Braite D., Sá G., Thurow H., Seixas F., Azevedo V., Portela R., Borsuk S. Assessment of the acid phosphatase CP01850 from Corynebacterium pseudotuberculosis in DNA and subunit vaccine formulations against caseous lymphadenitis. Arq. Bras. Med. Vet. E Zootec. 2020;72:199–207. doi: 10.1590/1678-4162-10790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1678-4162-10790</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanathan V., Badenoch-Jones P., Turk J. Complement activation by aluminium and zirconium compounds. Immunology. 1979;37:881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1457138</ArticleId><ArticleId IdType="pubmed">500133</ArticleId></ArticleIdList></Reference><Reference><Citation>Egwang T., Befus A. The role of complement in the induction and regulation of immune responses. Immunology. 1984;51:207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1454432</ArticleId><ArticleId IdType="pubmed">6363279</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y.J., Huang C.Y., Ho H.M., Huang M.H. Morphology and protein adsorption of aluminum phosphate and aluminum hydroxide and their potential catalytic function in the synthesis of polymeric emulsifiers. Colloids Surf. A Physicochem. Eng. Asp. 2020;608:125564. doi: 10.1016/j.colsurfa.2020.125564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfa.2020.125564</ArticleId><ArticleId IdType="pmc">PMC7481801</ArticleId><ArticleId IdType="pubmed">32929307</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell L.S., White J.L., Hem S.L. Stability of aluminium-containing adjuvants during aging at room temperature. Vaccine. 2000;18:2188–2192. doi: 10.1016/S0264-410X(00)00031-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(00)00031-1</ArticleId><ArticleId IdType="pubmed">10717337</ArticleId></ArticleIdList></Reference><Reference><Citation>Jendrek S., Little S.F., Hem S., Mitra G., Giardina S. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants. Vaccine. 2003;21:3011–3018. doi: 10.1016/S0264-410X(03)00109-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(03)00109-9</ArticleId><ArticleId IdType="pubmed">12798645</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang M.-F., Shi Y., Nail S.L., HogenEsch H., Adams S.B., White J.L., Hem S.L. Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits. Vaccine. 2001;19:2884–2889. doi: 10.1016/S0264-410X(00)00559-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(00)00559-4</ArticleId><ArticleId IdType="pubmed">11282199</ArticleId></ArticleIdList></Reference><Reference><Citation>Muthurania K., Ignatius A.A., Jin Z., Williams J., Ohtake S. Investigation of the sedimentation behavior of aluminum phosphate: Influence of pH, ionic strength, and model antigens. J. Pharm. Sci. 2015;104:3770–3781. doi: 10.1002/jps.24584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.24584</ArticleId><ArticleId IdType="pubmed">26205044</ArticleId></ArticleIdList></Reference><Reference><Citation>Aulton M. Pharmaceutics: The Science of Dosage form Design. Churchill Livingstone; Edinburg, UK: 1988. The design of dosage forms.</Citation></Reference><Reference><Citation>Rinella J.V., White J.L., Hem S.L. Effect of pH on the Elution of Model Antigens from Aluminum-Containing Adjuvants. J. Colloid Interface Sci. 1998;205:161–165. doi: 10.1006/jcis.1998.5648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jcis.1998.5648</ArticleId><ArticleId IdType="pubmed">9710509</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohr M., Remington E. The Science and Practice of Pharmacy, 21st Edition. J. Pharm. Technol. Jpn Off. Publ. Assoc. Pharm. Tech. 2006;22:133–134. doi: 10.1177/875512250602200217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/875512250602200217</ArticleId></ArticleIdList></Reference><Reference><Citation>Capelle M.A., Brügger P., Arvinte T. Spectroscopic characterization of antibodies adsorbed to aluminium adjuvants: Correlation with antibody vaccine immunogenicity. Vaccine. 2005;23:1686–1694. doi: 10.1016/j.vaccine.2004.09.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2004.09.031</ArticleId><ArticleId IdType="pubmed">15705473</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinko P.J. Martin’s Physical Pharmacy and Pharmaceutical Sciences. Lippincott Williams &amp; Wilkins; Baltimore, MD, USA: 2023.</Citation></Reference><Reference><Citation>Gutierro I., Hernandez R., Igartua M., Gascon A., Pedraz J. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine. 2002;21:67–77. doi: 10.1016/S0264-410X(02)00435-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(02)00435-8</ArticleId><ArticleId IdType="pubmed">12443664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanchan V., Panda A.K. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials. 2007;28:5344–5357. doi: 10.1016/j.biomaterials.2007.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2007.08.015</ArticleId><ArticleId IdType="pubmed">17825905</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann J.F., Shakir E., Carter K.C., Mullen A.B., Alexander J., Ferro V.A. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine. 2009;27:3643–3649. doi: 10.1016/j.vaccine.2009.03.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.03.040</ArticleId><ArticleId IdType="pubmed">19464545</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendorf J., Chesko J., Kazzaz J., Ugozzoli M., Vajdy M., O’Hagan D., Singh M. A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum. Vaccines. 2008;4:44–49. doi: 10.4161/hv.4.1.4886.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.4.1.4886</ArticleId><ArticleId IdType="pubmed">18438105</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung T., Kamm W., Breitenbach A., Hungerer K.-D., Hundt E., Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly (vinyl alcohol)-graft-poly (lactide-co-glycolide): Evaluation of antibody response after oral and nasal application in mice. Pharm. Res. 2001;18:352–360. doi: 10.1023/A:1011063232257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1011063232257</ArticleId><ArticleId IdType="pubmed">11442276</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagamoto T., Hattori Y., Takayama K., Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm. Res. 2004;21:671–674. doi: 10.1023/B:PHAM.0000022414.17183.58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:PHAM.0000022414.17183.58</ArticleId><ArticleId IdType="pubmed">15139524</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Hagan D.T. Vaccine Adjuvants: Preparation Methods and Research Protocols. Springer; Berlin/Heidelberg, Germany: 2000.</Citation></Reference><Reference><Citation>Mei C., Deshmukh S., Cronin J., Cong S., Chapman D., Lazaris N., Sampaleanu L., Schacht U., Drolet-Vives K., Ore M. Aluminum phosphate vaccine adjuvant: Analysis of composition and size using off-line and in-line tools. Comput. Struct. Biotechnol. J. 2019;17:1184–1194. doi: 10.1016/j.csbj.2019.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2019.08.003</ArticleId><ArticleId IdType="pmc">PMC6739432</ArticleId><ArticleId IdType="pubmed">31528298</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalbfleisch K., Deshmukh S., Mei C., Ore M., Williams W., Durowoju I., Duprez J., Morin S., Carpick B., Kirkitadze M. Identity, structure and compositional analysis of aluminum phosphate adsorbed pediatric quadrivalent and pentavalent vaccines. Comput. Struct. Biotechnol. J. 2019;17:14–20. doi: 10.1016/j.csbj.2018.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2018.11.006</ArticleId><ArticleId IdType="pmc">PMC6297905</ArticleId><ArticleId IdType="pubmed">30581540</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinella J.V.J., White J.L., Hem S.L. Effect of Anions on Model Aluminum-Adjuvant-Containing Vaccines. J. Colloid Interface Sci. 1995;172:121–130. doi: 10.1006/jcis.1995.1233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jcis.1995.1233</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinella J.V., Workman R.F., Hermodson M.A., White J.L., Hem S.L. Elutability of Proteins from Aluminum-Containing Vaccine Adjuvants by Treatment with Surfactants. J. Colloid Interface Sci. 1998;197:48–56. doi: 10.1006/jcis.1997.5230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jcis.1997.5230</ArticleId><ArticleId IdType="pubmed">9466843</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin R.B. The chemistry of aluminum as related to biology and medicine. Clin. Chem. 1986;32:1797–1806. doi: 10.1093/clinchem/32.10.1797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinchem/32.10.1797</ArticleId><ArticleId IdType="pubmed">3019589</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivananda N., Sundaran B. Studies on adsorption of diphtheria toxoid on aluminium phosphate gel. Indian J. Sci. Technol. 2010;3:248–249. doi: 10.17485/ijst/2010/v3i3.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.17485/ijst/2010/v3i3.19</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkanidis M., Pietersz G.A., Xiang S.D., Mottram P.L., Crimeen-Irwin B., Ardipradja K., Plebanski M. Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods. 2006;40:20–29. doi: 10.1016/j.ymeth.2006.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2006.05.018</ArticleId><ArticleId IdType="pubmed">16997710</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloat B.R., Sandoval M.A., Hau A.M., He Y., Cui Z. Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. J. Control. Release. 2010;141:93–100. doi: 10.1016/j.jconrel.2009.08.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2009.08.023</ArticleId><ArticleId IdType="pmc">PMC2789915</ArticleId><ArticleId IdType="pubmed">19729045</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittayanukulluk A., Jiang D., Regnier F.E., Hem S.L. Effect of microenvironment pH of aluminum hydroxide adjuvant on the chemical stability of adsorbed antigen. Vaccine. 2004;22:1172–1176. doi: 10.1016/j.vaccine.2003.09.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2003.09.037</ArticleId><ArticleId IdType="pubmed">15003645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y., Shi Y. Alum: An old dog with new tricks. Emerg. Microbes Infect. 2016;5:e25. doi: 10.1038/emi.2016.40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2016.40</ArticleId><ArticleId IdType="pmc">PMC4820675</ArticleId><ArticleId IdType="pubmed">27004761</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacardí D., Cosme K., Aldana L., Merino N., Suárez J., Mosqueda O., Urquiza D., Romero J., Madrigal R., Amaya R. Preclinical safety of the Quimi-Hib® vaccine adjuvanted with aluminum phosphate during product development. Biotecnol. Apl. 2013;30:111–124.</Citation></Reference><Reference><Citation>Lopes M., Caldas L. Young children with austim spectrum disorders: Can aluminium bodyburden cause metabolism disruption? Toxicol. Lett. 2011;205:S92. doi: 10.1016/j.toxlet.2011.05.338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxlet.2011.05.338</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomljenovic L., A Shaw C. Aluminum vaccine adjuvants: Are they safe? Curr. Med. Chem. 2011;18:2630–2637. doi: 10.2174/092986711795933740.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986711795933740</ArticleId><ArticleId IdType="pubmed">21568886</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan Z., Combadière C., Authier F.-J., Itier V., Lux F., Exley C., Mahrouf-Yorgov M., Decrouy X., Moretto P., Tillement O. Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. BMC Med. 2013;11:99. doi: 10.1186/1741-7015-11-99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-99</ArticleId><ArticleId IdType="pmc">PMC3616851</ArticleId><ArticleId IdType="pubmed">23557144</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomljenovic L. Aluminum and Alzheimer’s disease: After a century of controversy, is there a plausible link? J. Alzheimer’s Dis. 2011;23:567–598. doi: 10.3233/JAD-2010-101494.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-101494</ArticleId><ArticleId IdType="pubmed">21157018</ArticleId></ArticleIdList></Reference><Reference><Citation>Exley C., Mamutse G., Korchazhkina O., Pye E., Strekopytov S., Polwart A., Hawkins C. Elevated urinary excretion of aluminium and iron in multiple sclerosis. Mult. Scler. J. 2006;12:533–540. doi: 10.1177/1352458506071323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458506071323</ArticleId><ArticleId IdType="pubmed">17086897</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitkus R.J., King D.B., Hess M.A., Forshee R.A., Walderhaug M.O. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. Vaccine. 2011;29:9538–9543. doi: 10.1016/j.vaccine.2011.09.124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.09.124</ArticleId><ArticleId IdType="pubmed">22001122</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson-Welder J.H., Torres M.P., Kipper M.J., Mallapragada S.K., Wannemuehler M.J., Narasimhan B. Vaccine adjuvants: Current challenges and future approaches. J. Pharm. Sci. 2009;98:1278–1316. doi: 10.1002/jps.21523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.21523</ArticleId><ArticleId IdType="pmc">PMC8092333</ArticleId><ArticleId IdType="pubmed">18704954</ArticleId></ArticleIdList></Reference><Reference><Citation>Caulfield M.J., Shi L., Wang S., Wang B., Tobery T.W., Mach H., Ahl P.L., Cannon J.L., Cook J.C., Heinrichs J.H. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Hum. Vaccines. 2007;3:139–145. doi: 10.4161/hv.3.4.4309.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.3.4.4309</ArticleId><ArticleId IdType="pubmed">17581283</ArticleId></ArticleIdList></Reference><Reference><Citation>HogenEsch H., O’Hagan D.T., Fox C.B. Optimizing the utilization of aluminum adjuvants in vaccines: You might just get what you want. NPJ Vaccines. 2018;3:51. doi: 10.1038/s41541-018-0089-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-018-0089-x</ArticleId><ArticleId IdType="pmc">PMC6180056</ArticleId><ArticleId IdType="pubmed">30323958</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Das S., Schanen B., Seal S. Adjuvants in micro-to nanoscale: Current state and future direction. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2016;8:61–84. doi: 10.1002/wnan.1354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wnan.1354</ArticleId><ArticleId IdType="pubmed">26053286</ArticleId></ArticleIdList></Reference><Reference><Citation>Raponi A., Brewer J.M., Garside P., Laera D. Nanoalum adjuvanted vaccines: Small details make a big difference. Proc. Semin. Immunol. 2021;56:101544. doi: 10.1016/j.smim.2021.101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2021.101544</ArticleId><ArticleId IdType="pubmed">34895823</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazarizadeh A., Staudacher A.H., Wittwer N.L., Turnbull T., Brown M.P., Kempson I. Aluminium Nanoparticles as Efficient Adjuvants Compared to Their Microparticle Counterparts: Current Progress and Perspectives. Int. J. Mol. Sci. 2022;23:4707. doi: 10.3390/ijms23094707.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23094707</ArticleId><ArticleId IdType="pmc">PMC9101817</ArticleId><ArticleId IdType="pubmed">35563097</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B., Wang X., Ji Z., Wang M., Liao Y.P., Chang C.H., Li R., Zhang H., Nel A.E., Xia T. NADPH oxidase-dependent NLRP3 inflammasome activation and its important role in lung fibrosis by multiwalled carbon nanotubes. Small. 2015;11:2087–2097. doi: 10.1002/smll.201402859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smll.201402859</ArticleId><ArticleId IdType="pmc">PMC4420651</ArticleId><ArticleId IdType="pubmed">25581126</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Wang S., Gao M., Li R., Liu S. Multihierarchically profiling the biological effects of various metal-based nanoparticles in macrophages under low exposure doses. ACS Sustain. Chem. Eng. 2018;6:10374–10384. doi: 10.1021/acssuschemeng.8b01744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acssuschemeng.8b01744</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan J., Du G., He C., Jiang M., Mou X., Xue J., Sun X. Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination. J. Control. Release. 2020;326:297–309. doi: 10.1016/j.jconrel.2020.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.07.008</ArticleId><ArticleId IdType="pubmed">32659330</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z., Yang Y., Yu G., Zhu H., Xia X., Chen C., Fu D., Li M., Cheng G., Xue C. Engineering aluminum hydroxyphosphate nanoparticles with well-controlled surface property to enhance humoral immune responses as vaccine adjuvants. Biomaterials. 2021;275:120960. doi: 10.1016/j.biomaterials.2021.120960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2021.120960</ArticleId><ArticleId IdType="pubmed">34147722</ArticleId></ArticleIdList></Reference><Reference><Citation>Garon N., Mechelen M.V., Wettendorff M. Immunopotentiators in Modern Vaccines. Elsevier; Amsterdam, The Netherlands: 2006. Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt-10; pp. 161–177.</Citation></Reference><Reference><Citation>Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., Kielland A., Vosters O., Vanderheyde N., Schiavetti F. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 2009;183:6186–6197. doi: 10.4049/jimmunol.0901474.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901474</ArticleId><ArticleId IdType="pubmed">19864596</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapping R.I., Akashi S., Miyake K., Godowski P.J., Tobias P.S. Toll-Like Receptor 4, But Not Toll-Like Receptor 2, Is a Signaling Receptor for Escherichia and Salmonella Lipopolysaccharides. J. Immunol. 2000;165:5780–5787. doi: 10.4049/jimmunol.165.10.5780.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.165.10.5780</ArticleId><ArticleId IdType="pubmed">11067937</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004;5:987–995. doi: 10.1038/ni1112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1112</ArticleId><ArticleId IdType="pubmed">15454922</ArticleId></ArticleIdList></Reference><Reference><Citation>Malyala P., Laera D., Cianetti S., Bufali S., Aggravi M., Ianni E., Judge C., Otten G., Singh M., O’Hagan D.T. The preparation and physicochemical characterization of aluminum hydroxide/TLR7a, a novel vaccine adjuvant comprising a small molecule adsorbed to aluminum hydroxide. J. Pharm. Sci. 2018;107:1577–1585. doi: 10.1016/j.xphs.2018.01.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2018.01.024</ArticleId><ArticleId IdType="pubmed">29421216</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002;20:709–760. doi: 10.1146/annurev.immunol.20.100301.064842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.20.100301.064842</ArticleId><ArticleId IdType="pubmed">11861616</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D.S., Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity. 2013;39:1–10. doi: 10.1016/j.immuni.2013.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.07.012</ArticleId><ArticleId IdType="pubmed">23890059</ArticleId></ArticleIdList></Reference><Reference><Citation>Clapp T., Siebert P., Chen D., Braun L.J. Vaccines with aluminum-containing adjuvants: Optimizing vaccine efficacy and thermal stability. J. Pharm. Sci. 2011;100:388–401. doi: 10.1002/jps.22284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.22284</ArticleId><ArticleId IdType="pmc">PMC3201794</ArticleId><ArticleId IdType="pubmed">20740674</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty N., Ashokkumar D., Fayaz A., Ramakrishnan M. Trends in Adjuvant and Vaccine Delivery Systems. J. Infect. Dis. Ther. 2016;1:64–74.</Citation></Reference><Reference><Citation>He Q., Mitchell A.R., Johnson S.L., Wagner-Bartak C., Morcol T., Bell S.J. Calcium phosphate nanoparticle adjuvant. Clin. Diagn. Lab. Immunol. 2000;7:899–903. doi: 10.1128/CDLI.7.6.899-903.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.7.6.899-903.2000</ArticleId><ArticleId IdType="pmc">PMC95982</ArticleId><ArticleId IdType="pubmed">11063495</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>